Page 11 - Solid Biosciences News Today

NEW YORK--(BUSINESS WIRE)--Sep 30, 2022--

30.09.2022 - - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo - - Strong synergies expected by combining key assets, including ...

30.09.2022 - Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Solid Biosciences Inc. (“the Company”) (NasdaqGS: SLDB) with AavantiBio, Inc. pursuant to ...

The combined company will focus on the advancement of neuromuscular and cardiac programs for the treatment of Duchenne muscular dystrophy.

BioPharma

Global Gene Therapies For Rare Diseases market is expected to reach US$ 11,441.6 Million by 2030, with a CAGR of 21.7% during a forecast period of 2022-2030.

Otherwise they might end up a niche treatment for a small number of patients in rich countries | Briefing

Here is how late-stage gene therapy programs offer a glimpse into the future of rare disease medicine.


Private equity firm KKR teamed up with OMX Ventures to lead the seed investment in Replay, a company developing a suite of technologies that could overcome capacity limitations of adeno-associated viruses used for genetic medicines delivery. Duchenne muscular dystrophy is among the disease targets of the new startup.

/PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated...